Zobrazeno 1 - 8
of 8
pro vyhledávání: '"329"'
Autor:
Auro Viswabandya, Hans A. Messner, Dennis Dong Hwan Kim, Jieun Uhm, Marc Poch Martell, Elizabeth Shin, Jeffrey H. Lipton, Fotios V. Michelis
Publikováno v:
Blood. 126:3139-3139
Introduction: Chronic graft versus host disease (cGVHD) is one of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Several prognostic factors have been proposed to predict the outcomes of cGVHD including progres
Autor:
Myriam Rodríguez, Abel Berrios, Denisse Castro, Maria Elena Cabrera, Camila Peña, Carlos S. Chiattone, Victoria Otero, Fabiola Valvert Gamboa, Raul Gabus, Marialejandra Torres Viera, Teodoro Chisesi, Gregorio Ignacio, Brady E Beltran, Eduardo M. Sotomayor, Gabriel Borelli, Jorge J. Castillo, Sally Rose Paredes
Publikováno v:
Blood. 132:5395-5395
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of lymphoma in the world and corresponds to a heterogeneous entity, both from the clinical and molecular point of view, being its prognosis of survival very variable The
Autor:
Veronika Buxhofer-Ausch, Marco Ruggeri, Tiziano Barbui, Ayalew Tefferi, Juergen Thiele, Valerio De Stefano, Maria Luigia Randi, Guido Finazzi, Elisa Rumi, Alessandro Rambaldi, Heinz Gisslinger, Silvia Betti, Francesco Passamonti, Irene Bertozzi, Francesco Rodeghiero, Alessandro M. Vannucchi, Alessandra Carobbio
Publikováno v:
Blood. 120:5128-5133
Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk stratification for thrombosis in ET is 2-tiered and considers low- and high-risk categories
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin
Autor:
Jason Gotlib, Caramazza Domenica, Lisa Pieri, Tiziano Barbui, Timothy Devos, Paola Guglielmelli, Giorgina Specchia, Elisa Rumi, Margherita Maffioli, Mario Cazzola, Kiladjian Jean Jacques, Nicola Vianelli, Richard T. Silver, Rami S. Komrokji, Umberto Vitolo, Rambaldi Alessandro, Vannucchi Alessandro, Morra Enrica, Cristiana Pascutto, Valerio De Stefano, Barbara Mora, Cervantes Francisco, Francesco Passamonti, Marco Ruggeri
Publikováno v:
Blood. 124:1826-1826
Background. Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms that can progress to secondary myelofibrosis (MF), named post-PV (PPV) MF and post-ET (PET) MF. While outcome of primary myelofibrosis is d
Autor:
Pieter Sonneveld, Chrissy H. Y. Van Beurden-Tan, Philippe Moreau, Laura Rosiñol, Walter M Gregory, Michel van Agthoven
Publikováno v:
Blood. 124:2122-2122
INTRODUCTION Multiple Myeloma (MM) is an incurable disease and its treatment is characterized by treatment sequences (treatment lines). We questioned whether a health economic (HE) model could be developed that analyses treatment sequences (TS) rathe
Autor:
Joseph Pidala, Mukta Arora, Paul J. Martin, Xiaoyu Chai, Barry E. Storer, Jeanne Palmer, Madan Jagasia, Mary E.D. Flowers, Corey Cutler, Stephanie J. Lee, Sally Arai, Yoshihiro Inamoto, Steven Z. Pavletic, Georgia B. Vogelsang, Daniel J. Weisdorf
Publikováno v:
Blood. 122:4614-4614
The global severity score (GS) was devised by experts during the 2005 NIH Consensus for chronic graft-versus-host disease (GVHD) to reflect the overall severity of chronic GVHD at any time point. According to this scale, overall involvement is catego
Autor:
Heinz Haverkamp, Peter Borchmann, Jana Markova, Zdenek Kral, Andreas Engert, Carsten Kobe, Hans Theodor Eich, Josée M. Zijlstra, Anthony D. Ho, Harald Stein, Rolf-Peter Müller, Christoph Renner, Markus Dietlein, Volker Diehl
Publikováno v:
Blood. 118:589-589
Abstract 589FN2 Purpose: Intensified chemotherapy with eight cycles of BEACOPPescalated in advanced stage Hodgkin lymphoma (HL) is highly effective but also associated with relevant treatment related toxicity. In addition, the need for radiotherapy i